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Gene-modified cell therapies are transforming medicine. Over the last 18 months, notable clinical successes using antigen-targeting cellular immunotherapies have been achieved. However, another kind of gene modification has significant potential for the cell therapy industry. The development of fully controllable transgenes has enabled the creation of conditionally immortalized cells that can be expanded to clinical quantities in a stable and consistent fashion, yet can be returned to a normal, non-dividing state for therapeutic delivery to the patient. In this article, we discuss some of the key technologies that have been used to create conditionally immortalized cells for clinical development.
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The pressure and need to developm stable cell lines as biomedical research tools has triggered numerous approaches to produce stable, well-characterized cells. Big Pharma in particular relies on stable cell lines for drug screening and toxicology studies. Whilst embryonic stem cells and induced pluripotent stem cells invoke some powerful arguments for their utility, due to the large numbers of cells that can be generated and, in case of the latter, the ability to create patient-or disease-specific attributes to be studied, there are also some limitations with respect to consistent and reliable differentiation into target cells of interest. To this end, production of cell lines using primary cells from a more advanced stage of development than those of the early embryo, coupled with inducible transgene technologies that can impart regulatory control over cell division, offer an alternative strategy.
Conditional immortalization uses inducible transgene technology to create a cells that can be expanded in a consistent fashion when the transgene is active. If the transgene was permanently activated then the cells would, in theory, continuously divide. However, it is critical for conditional immortalization technology that the transgene is operator controllable so when desired clinical quantities of cell material are achieved, the transgene can be de-activated by the
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operator, returning the cells to a normal, post-mitotic state. This ensures that the cell formulation delivered to the patient is safe and carries negligible risk of cancer, overcoming the major concern for constitutively immortalized cells; cells with an infinite proliferative potential could become cancerous if they acquire oncogenic mutations.
Conditional immortalization involves inserting a modified gene that can be regulated by a defined reagent, controlled by the operator. In one set of conditions where the reagent is present, the transgene is active and the cells divide ceaselessly. In a second set of conditions where the reagent is removed, the cells are no longer immortal but have the potential to behave as would be expected under normal conditions such as undergoing differentiation (Figure 1) .
A natural progression from utility as biomedical research tools has been to develop conditionally immortalized cells as therapeutics. Although still in early development with few cell lines developed, some of these candidate therapies are already being utilized in pre-clinical and clinical studies with notable success. An overview of technologies, methods and associated patents is presented in Tables 1-3 & Figure 2 . Notable progress includes Phase 2 trials of conditionally immortalized cells for the treatment of ischemic stroke [1] and data so far indicates safe and effective outcomes in patients [2] . Building on this success more broadly across the industry and demonstrating that conditional immortalization tools are safe via complete inactivation of the transgene prior to delivery to patients, will be critical for building a successful healthcare tool for the industry and the patient. It wasn't until the advent of genetic engineering and procedures for the delivery of transgenes via DNA transfection or by viruses to insert desired immortalizing genes into the genome that scientists were able to create immortalized cells that were not derived from tumors. There is no single universal method to immortalize equally every candidate cell type for therapy. The type of cell and species from which it is obtained are factors that affect this. For example, many fundamental studies have been conducted in mice, but mouse cells have long telomeres so it is suggested that they do not undergo replicative senescence as human cells do, but stress-induced senescence. Even though stress activation of the p53 and pRB pathways are common f TAM uses a combination of growth factors and 4-OHT to activate the c-MycER transgene. When activated cells divide. In the absence of 4-OHT, c-MycER is inactivated and the cells revert to a normal phenotype. tsA58 is a temperature sensitive switch that is permissive for cell division at 33°C but inactivated at 39°C. Cre/Lox technology involves engineering a transgene flanked by LoxP sites. The transgene is active until Cre recombinase is added, at which point the flanked DNA is excised. hTERT catalyses the addition of telomeric repeats to the end of the telomeres, preventing telomere-dependent senescence. Tet on/off systems utilize tetracycline responsive elements (TRE) that comprise a tet Operator and minimal promoter. The activation of the transgene and hence cell division is dependent on tetracycline or doxycycline as a cue for activation (tet on) or inactivation (tet off). rtTA: Reverse tetracycline transactivator, tTA: Tetracycline transactivator; tetO: tet operator; 4-OHT: 4-hydroxytamoxifen, hTERT: human telomerase reverse transcriptase.
IMMORTALIZATION IS INDUCED BY MULTIPLE MECHANISMS
as the Simian Virus 40 (SV40) large T antigen, the E7 protein of human papilloma virus type 16 (HPV16), Myc (both retrovirus-derived v-myc and the cellular homolog c-myc) and the catalytic subunit of human telomerase (human telomerase reverse transcriptase; hTERT) [6,9-12].
Myc activation
c-myc, along with the viral homolog v-myc, exerts regulatory control over a range of cell functions, but in particular it drives cell cycle entry and cell division. This makes it an attractive target for creating stable cell lines and in fact c-myc is one of the four Yamanaka factors used to create induced pluripotent stem cells [13] . Mutations in the myc gene that result in it being constitutively expressed are associated with oncogenic transformation, resulting in cancer. Therefore, controlled expression of c-myc is desired, and preferably under full operator control. The conditional immortalization technology c-MycER TAM consists of a fusion gene that encodes a chimeric protein, composed of c-myc and an N-terminal truncated hormone binding domain of a mutant murine estrogen receptor (G525R), which can no longer bind to 17β-estradiol and estrogen, but is responsive to activation by the presence of the synthetic estrogen-like agonist 4-hydroxytamoxifen (4-OHT) [14,15].
In contrast with its wild-type version, the hormone binding domain of the mutant G525R has 1,000-fold lower binding affinity to estradiol, but retains its affinity to 4-OHT due to an amino acid change from glycine to arginine in the position 525
[15]. This means that culturing cells in the presence of 4-OHT promotes c-myc activity and subsequent cell division, whereas in the absence of 4-OHT, the cells revert to a non-activated state and can undergo maturation as normal cells do.
Before the development of c-MycER TAM , the application of wild-type hormone receptors for fusion protein generation with viral antigens presented significant challenges. These included concern about inadequate control of activation due to presence of estrogens in serum and weak agonists in basal culture media. Moreover, circulating hormones could activate the c-MycER-TAM in vivo and drive continued proliferation, posing a safety risk [14] .
The synthesis of c-MycER The process is likely to involve two components, a mitotic 'clock' that counts the number of divisions and entry into a post-mitotic state.
In human somatic cells, the progressive shortening of telomeres, short repetitive sequences at the ends of chromosomes, with each cell division has been proposed to be the mitotic clock [39]. Human telomeres comprise multiple tandem repeats of TTTAGG located at chromosome ends. They are dependent on the enzyme telomerase to maintain their length, but as human somatic cells do not express telomerase at levels sufficient to maintain the telomeres, they shorten by around 50 base pairs at each cell division [10,40]. Collectively, telomere loss in conjunction with the lack of telomerase activity is the mitotic clock responsible for limiting the number of divisions before senescence [3,7].
Although it was originally proposed that reconstitution of telomerase activity using hTERT was sufficient for immortalization of primary human cells [3], others found that reconstitution of telomerase alone could not, and in these instances secondary inactivation of regulator pathways such as p16 and pRB was required [8,41,42] . In addition, the studies assessed constitutive telomerase activation. However, telomerase has, in combination with other conditional transgenes, proven very successful in supporting conditional immortality. The O'Hare et al. study showed that ectopic expression of hTERT or U19tsA58 Tag alone was not sufficient for immortalization of freshly isolated human cells but a combination of the genes resulted in efficient generation of immortal cells lines irrespective of the order in which they were introduced. However, the order and timing of introducing the two genes did influence the genetic stability of the cells, which is a significant consideration for generating safe cells for therapy. They further showed that maintenance of immortalization depended on a continued expression of functional U19tsA58 Tag, with hTERT alone unable to maintain growth when the U19t-sA58 Tag was inactivated [10].
TEMPERATURE-SENSITIVE SV40 VERSUS TELOMERASE
U19tsA58 Tag was also capable of creating a conditional immortal cell line from rat neonatal optic nerve there was capable of differentiating into oligodendrocytes [45]. The same group also used U19t-sA58 Tag to study the heterogeneity of candidate regenerative olfactory ensheathing cells from olfactory bulb and lamina propria [46] . These studies in rat using cells that are difficult to culture and characterize offer promise for human cell line generation for regenerative purposes.
COMBINING hTERT & U19tsA58 TAG
The demonstration that hTERT and U19tsA58 Tag synergized to efficiently immortalize human cells led to the development of a bicistronic retrovirus, which simultaneously expresses hTERT, U19tsA58 Tag and an antibiotic resistance gene. This virus is highly efficient for immortalization of human cells. From this work, US Patent 6399384 B1 was assigned to ReNeuron Ltd and the Ludwig Institute for Cancer Research (Table 3) .
Although this vector is highly efficient at immortalizing human cells, the resulting cells had a higher number of chromosomes than normal, even though both genes had been transduced simultaneously. The likely reason for this karyotypic instability was unmasked using a yeast 2-hybrid screen and rodent studies. It was found that Tag interacts with the spindle assembly checkpoint protein, Bub 1, and 
A potential solution to this problem of karyotypic instability would be to construct an SV40 triple mutant that in addition to the U19tsA58 Tag double mutant, lacks the Bub1 interaction site (U19dl89-97tsA58). A very simple way to facilitate making cell lines using such a mutant would be to develop a bicistronic vector, as described in US Patent 6399384 B1.
CRE-LOXP SYSTEM FOR REVERSIBLE IMMORTALIZATION
The potential safety concerns with temperature sensitive genetic tools for clinical application, led to the consideration of site-specific recombination systems to excise the oncogene [ However, as the system requires an exhaustive selection process, tamoxifen-dependent Cre recombinases have been incorporated in order to achieve a better-controlled excision of the oncogene 
TET-ON & TET-OFF: TRAN-SCRIPTION REGULATION OF IMMORTALIZATION
Conditional immortalization has also been achieved by the use of transcription-regulated systems. The most widely used have been derived using the prokaryotic tetra cycline repression system. They utilize a tet repressor (tetR) protein, that binds strongly to a sequence called the tetracycline operator (tetO) in the absence of the antibiotic (tet racycline or doxycycline). When the antibiotic is present, it binds to the repressor, thereby inhibiting it's binding to the tetO. The first system available was called 'Tet-Off', and was developed in HeLa cells [62] . In this system the tet repressor binding site is inserted between the promoter and the transcriptional start site such that binding of the repressor sterically blocks transcription. However the steric hindrance is readily overcome upon addition of small amounts of tetracycline and doxycycline that prevent binding of the tetR to the tetO, thereby inducing reporter gene expression. However, Tet-Off systems require constant doses of tetracycline to activate transcription and also easily lose tet regulation due to loss of the tetR. To circumvent this, 'Tet-On' systems were generated [63] . Gossen and Bu jard fused the tetR with the C-terminal activation domain of the virion protein 16 (VP16) from herpes simplex virus (HSV) to generate a hybrid transactivator (tTA) that stimulates promoters fused to tetO sequences. A modification of four amino acids resulted in a reverse tetracycline transactivator (rtTA), which binds to tetO only in the presence of tet racycline or doxycycline. Oncogenes (c-Myc and Tag) and telomerase (hTERT) were initially tested in Tet-based immortalization systems for mouse embryo fibroblasts (MEFs), murine kidney cells (293T), mouse embryonic stem cells and human endothelial cells [64] [65] [66] [67] .
More recently, mesenchymal stromal cells (MSCs) have been immortalized with tetracycline inducible systems. Tetracycline-inducible hTERT-expressing MSC cell lines were created by Piper et al. [68] . These cell lines retained multipotency and immortalization was dependent on telomere elongation. However, additional screening was necessary to determine which clones showed the lowest levels of hTERT basal expression. Leakiness is the most criticized drawback of tetracycline-based expression systems.
A conditionally immortalized MSC line was generated by lentiviral transfection of Tag-hTERT in conjunction with a doxycycline/ tetracycline-induction (Tet-On) system [69] . These cells were used to study senescence-associated DNA methylation (SA-DNAm) changes, and could be maintained in culture for 80 days without any sign of senescence. Removal of doxycycline in the media resulted in immediate growth arrest, and further expression of senescence-associated ß-galactosidase. Telomere length increased significantly when the cells were exposed to the antibiotic and were not affected with SA-DNAm.
CONCLUSION
The emerging cell and gene therapy industry will grow stronger by having access to new and powerful molecular tools that enable the creation of conditionally immortal therapeutic cell lines from adult cells that have potential curative or regenerative effects in their natural state, but that cannot be expanded to consistently high yields in this natural state. Immortalization on its own carries concerns associated with genetic instability and transformation to a cancer phenotype. The conditional step overcomes this by utilizing a fully controllable mechanism that removes or permanently silences the immortalization gene prior to delivery.
There are a range of different molecular biology tools that can be used to create conditionally immortalized cells that are operator controllable, via manipulation of reagents and environment, which offer potential solutions to the industrial scale generation of cells for patients.
Clearly there is commercial value in the creation of conditionally immortalized cell lines for therapeutic application. There are challenges to be addressed for other technologies, such as ensuring that the transgene is completely silenced prior to delivering cells to the patient. The lessons from early prominent successes like ReNeuron's will hopefully unlock development opportunities more widely across the industry through increased understanding of how to generate the necessary safety data, navigate regulatory pathways and create commercially sustainable manufacturing processes that are cost effective and have a sound reimbursement model. f 
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